Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
75 participants
INTERVENTIONAL
2021-03-15
2022-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between Intrathecal and Intravenous Dexmedetomidine
NCT04374318
Propofol Versus Dexmedetomidine for Sedation of Cancer Patients Undergoing ERCP
NCT06409104
Epidural Anesthesia for Gynecological Surgeries
NCT04174872
Comparison Between Dexmedetomidine and Propofol for Patients in the Intensive Care Unit After Abdominal Surgery
NCT02874768
Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block
NCT07263165
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Heavy Bupivacaine plus normal saline
2.5 ml of 0.5% hyperbaric Bupivacaine plus 0.5 ml 0.9 % saline
Bupivacain
12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
Heavy Bupivacaine plus dexmedetomidine
2.5 ml of 0.5% hyperbaric Bupivacaine plus 5 micrograms dexmedetomidine in 0.5 ml 0.9 % saline
Dexmedetomidine
5 micrograms intrathecal dexmedetomidine
Bupivacain
12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
Heavy Bupivacaine plus midazolam
2.5 ml of 0.5% hyperbaric Bupivacaine plus 2 milligrams midazolam in 0.5 ml 0.9 % saline
Midazolam
2 milligrams intrathecal midazolam
Bupivacain
12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
5 micrograms intrathecal dexmedetomidine
Midazolam
2 milligrams intrathecal midazolam
Bupivacain
12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I, II, III.
* Age 20 to 70 year
* Healthy volunteers
Exclusion Criteria
* ASA IV, V.
* patients' refusal.
* patients with coagulopathy.
* patients with severe valvular stenosis
* patients with infection at site of injection
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Said Nasef Zedan
assistant lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed Elwasef, MD
Role: STUDY_DIRECTOR
NCI Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National cancer institute
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AP210330102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.